To study the regulation of IL-8 production and release of eosinophil-derived neurotoxin (EDN) by normal blood eosinophils, we isolated eosinophils from healthy individuals and stimulated them with immobilized secretory IgA with or without exogenous IL-5 for 3, 12, and 24 h, and with different concentrations of ionomycin for 24 h. Eosinophils cultured with secretory IgA for 3 and 12 h showed strong expression of mRNA for IL-8 by reverse transcription polymerase chain reaction. Exogenous IL-5 enhanced mRNA for IL-8 expression by eosinophils after 24 h of incubation. IL-8 secretion increased in a time-dependent manner throughout the 24 h of observation; in contrast, EDN release reached a plateau value after 12 h. Furthermore, at least 2 μM ionomycin was necessary for induction of IL-8 secretion, whereas 0.5 μM induced detectable EDN release by eosinophils. These results suggest that the mechanism of eosinophil degranulation may be different from those of cytokine secretion.

Keywords:
Eosinophil, IL-8, Eosinophil-derived neurotoxin, IgA, secretory, Ionomycin
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.